Marktanalyse - Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016

Global Markets Direct
12.2016
47 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections — Pipeline Review, H2 2016, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline landscape.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warm to the touch, fever and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 8 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview 7

Therapeutics Development 8

Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview 8

Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis 9

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Development by Companies 10

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 11

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Development by Companies 14

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Investigation by Universities/Institutes 15

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development 16

Destiny Pharma Ltd 16

Galapagos NV 17

MGB Biopharma Ltd 18

Syntiron LLC 19

Techulon Inc 20

Valevia UK Ltd 21

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

acALY-18 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

exeporfinium chloride - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

GLPG-1492 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

MGBBP-3 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

MH-003 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Siderocillin - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Staphylococcus aureus vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

VAL-301 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects 43

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products 44

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones 45

Featured News & Press Releases 45

Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 4





List of Tables

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H2 2016 8

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Ltd, H2 2016 16

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Galapagos NV, H2 2016 17

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Ltd, H2 2016 18

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Syntiron LLC, H2 2016 19

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon Inc, H2 2016 20

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, H2 2016 43

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, H2 2016 44





List of Figures

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H2 2016 8

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus